Validation Data Gallery
Tested Applications
| Positive WB detected in | human brain tissue |
| Positive IHC detected in | human gliomas tissue Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0 |
| Positive IF/ICC detected in | SH-SY5Y cells |
Recommended dilution
| Application | Dilution |
|---|---|
| Western Blot (WB) | WB : 1:500-1:2000 |
| Immunohistochemistry (IHC) | IHC : 1:20-1:200 |
| Immunofluorescence (IF)/ICC | IF/ICC : 1:50-1:500 |
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, Check data in validation data gallery. | |
Published Applications
| WB | See 2 publications below |
Product Information
51051-2-AP targets GALC in WB, IF, IHC, ELISA applications and shows reactivity with human, mouse samples.
| Tested Reactivity | human, mouse |
| Cited Reactivity | human |
| Host / Isotype | Rabbit / IgG |
| Class | Polyclonal |
| Type | Antibody |
| Immunogen | GALC fusion protein Ag0483 相同性解析による交差性が予測される生物種 |
| Full Name | galactosylceramidase |
| Calculated molecular weight | 668 aa, 76 kDa |
| Observed molecular weight | 30 kDa |
| GenBank accession number | BC036518 |
| Gene Symbol | GALC |
| Gene ID (NCBI) | 2581 |
| RRID | AB_2108526 |
| Conjugate | Unconjugated |
| Form | Liquid |
| Purification Method | Antigen affinity purification |
| UNIPROT ID | P54803 |
| Storage Buffer | PBS with 0.02% sodium azide and 50% glycerol pH 7.3. |
| Storage Conditions | Store at -20°C. Aliquoting is unnecessary for -20oC storage. |
Background Information
Galactosylceramidase (Galc) is a lysosomal enzyme involved in the catabolism of galactosylceramide, a major lipid in myelin, kidney, and epithelial cells of the small intestine and colon. The normal GALC mRNA encodes the 80 kDa precursor, which is processed into 50 and 30 kDa subunits. Mutation of GALC gene will lead to Krabbe disease (globoid cell leukodystrophy), an autosomal recessive neurodegenerative disorder that affects both the central and peripheral nervous system due to an enzymatic defect of galactocerebrosidase. This antibody is specific to GALC.
Protocols
| Product Specific Protocols | |
|---|---|
| WB protocol for GALC antibody 51051-2-AP | Download protocol |
| IHC protocol for GALC antibody 51051-2-AP | Download protocol |
| IF protocol for GALC antibody 51051-2-AP | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |
Publications
| Species | Application | Title |
|---|---|---|
J Hum Genet Chaperone therapy for Krabbe disease: potential for late-onset GALC mutations. | ||
Gene Late-onset Krabbe disease is predominant in Japan and its mutant precursor protein undergoes more effective processing than the infantile-onset form. | ||
Biomater Adv Micro/nano-patterns for enhancing differentiation of human neural stem cells and fabrication of nerve conduits via soft lithography and 3D printing |